PD‐1 targeting in cancer immunotherapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|23|E1-E3

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.23, 2013-12, pp. : E1-E3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunologic and Clinical Effects of Targeting PD‐1 in Lung Cancer

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 214-223

John Wiley & Sons Inc

Access to resources Recommend Favorite

Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy

By  

JOURNAL OF INTERNAL MEDICINE, Vol. 283, Iss. 2, 2018-02 ,pp. : 110-120

John Wiley & Sons Inc

Access to resources Recommend Favorite

Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management

By  

Current Drug Safety, Vol. 11, Iss. 1, 2016-03 ,pp. : 62-68

Bentham Science Publishers

Access to resources Recommend Favorite

PD-1/PD-L1 Pathway in Breast Cancer

By  

Oncology Research and Treatment, Vol. 40, Iss. 5, 2017-03 ,pp. : 294-297

Karger

Access to resources Recommend Favorite

Cancer immunotherapy

By Baxevanis Constantin N.   Perez Sonia A.   Papamichail Michael  

Critical Reviews in Clinical Laboratory Sciences, Vol. 46, Iss. 4, 2009-08 ,pp. : 167-189

Informa Healthcare

Access to resources Recommend Favorite